Enliven Therapeutics Files 2024 10-K
Ticker: ELVN · Form: 10-K · Filed: Mar 13, 2025 · CIK: 1672619
| Field | Detail |
|---|---|
| Company | Enliven Therapeutics, Inc. (ELVN) |
| Form Type | 10-K |
| Filed Date | Mar 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
Enliven Therapeutics filed its 2024 10-K. Check financials.
AI Summary
Enliven Therapeutics, Inc. filed its 2024 10-K on March 13, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as IMARA Inc. until April 19, 2016, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 6200 Lookout Road, Boulder, CO 80301.
Why It Matters
This filing provides a comprehensive overview of Enliven Therapeutics' financial performance and business operations for the fiscal year 2024, crucial for investors and stakeholders to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a standard annual report filing with no immediate red flags or significant new disclosures that would indicate elevated risk.
Key Numbers
- 0000950170-25-038758 — Accession Number (Unique identifier for the filing)
- 88 — Public Document Count (Number of documents included in the filing)
- 001-39247 — SEC File Number (SEC's file number for the company)
Key Players & Entities
- Enliven Therapeutics, Inc. (company) — Filer of the 10-K
- IMARA Inc. (company) — Former name of Enliven Therapeutics, Inc.
- 2024-12-31 (date) — Fiscal year end
- 2025-03-13 (date) — Filing date
- 6200 Lookout Road, Boulder, CO 80301 (address) — Business and mailing address
FAQ
What is the primary business of Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification code [2834].
When did the company change its name from IMARA Inc.?
The company's name was changed from IMARA Inc. on April 19, 2016.
What is the fiscal year end for this 10-K filing?
The Conformed Period of Report, which is the fiscal year end, is December 31, 2024.
Where is Enliven Therapeutics, Inc. located?
The company's business and mailing address is 6200 Lookout Road, Boulder, CO 80301.
What is the SEC Act under which this filing was made?
This filing was made under the 1934 Act.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 13, 2025 regarding Enliven Therapeutics, Inc. (ELVN).